Optimizing drug combination and mechanism analysis based on risk pathway crosstalk in pan cancer

Sci Data. 2024 Jan 16;11(1):74. doi: 10.1038/s41597-024-02915-y.

Abstract

Combination therapy can greatly improve the efficacy of cancer treatment, so identifying the most effective drug combination and interaction can accelerate the development of combination therapy. Here we developed a computational network biological approach to identify the effective drug which inhibition risk pathway crosstalk of cancer, and then filtrated and optimized the drug combination for cancer treatment. We integrated high-throughput data concerning pan-cancer and drugs to construct miRNA-mediated crosstalk networks among cancer pathways and further construct networks for therapeutic drug. Screening by drug combination method, we obtained 687 optimized drug combinations of 83 first-line anticancer drugs in pan-cancer. Next, we analyzed drug combination mechanism, and confirmed that the targets of cancer-specific crosstalk network in drug combination were closely related to cancer prognosis by survival analysis. Finally, we save all the results to a webpage for query ( http://bio-bigdata.hrbmu.edu.cn/oDrugCP/ ). In conclusion, our study provided an effective method for screening precise drug combinations for various cancer treatments, which may have important scientific significance and clinical application value for tumor treatment.

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Computational Biology / methods
  • Drug Combinations
  • Humans
  • MicroRNAs*
  • Neoplasms* / drug therapy
  • Neoplasms* / genetics
  • Neoplasms* / pathology

Substances

  • Antineoplastic Agents
  • Drug Combinations
  • MicroRNAs